Antisense oligonucleotides to therapeutically target sars-cov-2 infection

HIGHLIGHTS

• who: Yuanyuan Qiao and colleagues from the Editor:, University of South Florida have published the article: Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection, in the Journal: PLOS ONE of 31/Oct/2022
• what: In this study ASOs targeted against the SARS-CoV-2 genome and host entry factors ACE2 and TMPRSS2 were designed and tested for their ability to inhibit cellular infection by SARS-CoV-2.
• how: These results indicated that H1437 CAL27 SNU-1066 and LNCaP were competent ASO free uptake cell lines for the subsequent SARS-CoV-2 ASO . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.